Treatment of metastatic urothelial cancer: Opportunities for drug discovery and development

BJU International

Volumn 102, Issue 9B, 2008, Pages 1354-1360

  Sonpavde, Guru ^a   Sternberg, Cora N ^b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

Biological agents; Chemotherapy; Urothelial carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DASATINIB; DOCETAXEL; DOXORUBICIN; E 7389; ERLOTINIB; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; IXABEPILONE; LAPATINIB; METHOTREXATE; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VINBLASTINE; VINFLUNINE;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ANEMIA; BLADDER CANCER; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; COMBINATION CHEMOTHERAPY; CONSTIPATION; CYSTECTOMY; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; METASTASIS; MONOTHERAPY; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPENIC SEPSIS; PRIORITY JOURNAL; PROGNOSIS; RECURRENT CANCER; REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; SEPSIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; UROGENITAL TRACT CANCER; VOMITING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; DNA-BINDING PROTEINS; DRUG DESIGN; ENDONUCLEASES; HUMANS; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; SURVIVAL RATE; TECHNOLOGY, PHARMACEUTICAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UROLOGIC NEOPLASMS;

EID: 54049101617     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07982.x     Document Type: Review

References (43)

1. Saxman SB, Propert KJ, Einhorn LH et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997 17 : 3068 77
2. Sternberg CN, de Mulder P, Schornagel JH et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006 42 : 50 4
3. von der Maase H, Senegelov L, Roberts JT et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005 23 : 4602 8
4. Bellmunt J, von der Maase H, Mead GM et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007 25 (18S LBA5030
5. Grossman HB, Natale RB, Tangen CM et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003 349 : 859 66
6. Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996 156 : 1606 8
7. Vaughn DJ, Broome CM, Hussain M et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002 20 : 937 40
8. McCaffrey JA, Hilton S, Mazumdar M et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997 15 : 1853 7
9. Lorusso V, Pollera CF, Antimi M et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998 34 : 1208 12
10. Albers P, Siener R, Hartlein M et al. Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma - prognostic factors for response and improvement of quality of life. Onkologie 2002 25 : 47 52
11. Sternberg CN, Calabrò F, Pizzocaro G et al. Chemotherapy with every 2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001 92 : 2993 8
12. Dogliotti L, Carteni G, Siena S et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007 52 : 134 41
13. Petrioli R, Frediani B, Manganelli A et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996 77 : 344 51
14. Bellmunt J, Ribas A, Eres N et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997 80 : 1966 72
15. Dreicer R, Manola J, Schneider DJ et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003 97 2743 7
16. Ardavanis A, Tryfonopoulos D, Alexopoulos A et al. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Br J Cancer 2005 92 : 645 50
17. Li J, Juliar B, Yiannoutsos C et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005 23 : 1185 91
18. Meluch AA, Greco FA, Burris HA 3rd et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network. J Clin Oncol 2001 19 : 3018 24
19. Bellmunt J, Paz-Ares L, Cuello M et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007 18 : 522 8
20. Bajorin DF, Dodd PM, Mazumdar M et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999 17 : 3173 81
21. Bajorin DF, Ostrovnaya I, Iasonos A et al. A nomogram predicting survival of patients (pts) with metastatic or unresectable urothelial cancer (UC) treated with cisplatin-based chemotherapy. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007 25 (18S): 5055
22. Culine S, Theodore C, De Santis M et al. A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 2006 10 : 1395 401
23. Sweeney CJ, Roth BJ, Kabbinavar FF et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol 2006 24 : 3451 7
24. Galsky MD, Mironov S, Iasonos A et al. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs 2007 25 : 265 70
25. Dreicer R, Li S, Manola J et al. Phase 2 trial of epothilone B analog BMS-247550 (ixabepilone) in advanced carcinoma of the urothelium (E3800): a trial of the eastern cooperative oncology group. Cancer 2007 110 : 759 63
26. Winquist E, Vokes E, Moore MJ et al. A phase II study of oxaliplatin in urothelial cancer. Urol Oncol 2005 23 : 150 4
27. Paz-Ares L, Tabernero J, Moyano A et al. Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a Phase II trial. Ann Oncol 1998 9 : 292
28. von der Maase H, Lehmann J, Gravis G et al. A phase II trial of pemetrexed plus gemcitabine in locally advanced and/or metastatic transitional cell carcinoma of the urothelium. Ann Oncol 2006 17 : 1533 8
29. Theodore C, Bidault F, Bouvet-Forteau N et al. A phase II monocentric study of oxaliplatin in combination with gemcitabine (GEMOX) in patients with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. Ann Oncol 2006 17 : 990 4
30. Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005 23 : 7785 93
31. Lonn U, Lonn S, Friberg S et al. Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995 1 : 1189 94
32. Hussain MH, MacVicar GR, Petrylak DP et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol 2007 25 : 2218 24
33. Inoue K, Slaton JW, Davis DW et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel. Clin Cancer Res 2000 6 : 2635 43
34. Sriplakich S, Jahnson S, Karlsson MG. Epidermal growth factor receptor expression: predictive value for the outcome after cystectomy for bladder cancer? BJU Int 1999 83 : 498 503
35. Inoue K, Slaton JW, Perrotte P et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000 6 : 4874 84
36. Philips G, Sanford B, Halabi S et al. Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): analysis of the second cohort of CALGB 90102. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006 24 (18S 4578
37. Wülfing C, Machiels J, Richel D et al. A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. ASCO Annual Meeting Proceedings. J Clin Oncol 2005 23 (16S 4594
38. Sonpavde G, Jian W, Liu H et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2008 (Epub ahead of print)
39. Gallagher DJ, Milowsky MI, Gerst SR et al. Phase II study of sunitinib in patients (pts) with relapsed or refractory urothelial carcinoma (UC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007 25 (18S): 5080
40. Zhu K, Pino MS, Siefker-Radtke AO et al. AG-013736, a novel VEGF receptor and PDGF receptor inhibitor with potent activity against human bladder carcinoma in vitro and in vivo. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006 24 (18S 13109
41. Shen SS, Smith CL, Hsieh JT et al. Expression of estrogen receptors-alpha and - beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006 106 : 2610 6
42. Sonpavde G, Okuno N, Weiss H et al. Efficacy of selective estrogen receptor modulators in nude mice bearing human transitional cell carcinoma. Urology 2007 69 : 1221 6
43. Dash A, Pettus JA, Bochner BH et al. Efficacy of neo-adjuvant gemcitabine plus cisplatin (GC) in muscle-invasive urothelial cancer (UC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007 25 (18S 5077